


UPDATE ON SACUBITRIL/VALSARTAN (ENTRESTO[®])



The HSE introduced a reimbursement application system for sacubitril/valsartan (Entresto[®]) in December 2017. The aim of the reimbursement application is to provide adult patients who have symptomatic chronic heart failure with reduced ejection fraction, with access to reimbursement support for sacubitril/valsartan (Entresto[®]).

In September 2023, 6,513 patients were accessing sacubitril/valsartan under the Community Drug Schemes. Between December 2017 and September 2023, expenditure on sacubitril/valsartan (Entresto[®]) on the Community Drug Schemes was €34.3 million.

November 2023

HSE Medicines Management Programme.